Mircea C. Popescu
24Patents
19h-index
29Co-inventors
81Inventor score
Filing activity: Aug 8, 1983 → May 22, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4708861A | Liposome-gel compositions | Emerging Cross-Sectional Technologies | 216 | Expired |
| US4610868A | Lipid matrix carriers for use in drug delivery systems | Emerging Cross-Sectional Technologies | 201 | Expired |
| US4588578A | Lipid vesicles prepared in a monophase | Emerging Cross-Sectional Technologies | 183 | Expired |
| US5169637A | Stable plurilamellar vesicles | Emerging Cross-Sectional Technologies | 146 | Expired |
| US4721612A | Steroidal liposomes | Emerging Cross-Sectional Technologies | 136 | Expired |
| US4981692A | Therapeutic treatment by intramammary infusion | Emerging Cross-Sectional Technologies | 123 | Expired |
| US5154930A | Pharmacological agent-lipid solution preparation | Emerging Cross-Sectional Technologies | 110 | Expired |
| US5030453A | Stable plurilamellar vesicles | Human Necessities | 102 | Expired |
| US6090406A | Potentiation of immune responses with liposomal adjuvants | Emerging Cross-Sectional Technologies | 100 | Expired |
| US5059591A | Drug preparations of reduced toxicity | Human Necessities | 100 | Expired |
| US5000958A | Enhancement of pharmaceutical activity | Emerging Cross-Sectional Technologies | 90 | Expired |
| US5100662A | Steroidal liposomes exhibiting enhanced stability | Emerging Cross-Sectional Technologies | 79 | Expired |
| US4897384A | Drug preparations of reduced toxicity | Human Necessities | 61 | Expired |
| US4891208A | Steroidal liposomes | Emerging Cross-Sectional Technologies | 53 | Expired |
| US5916588A | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use | Human Necessities | 50 | Expired |
| US5009819A | Taste moderating composition | Human Necessities | 34 | Expired |
| US6352716B1 | Steroidal liposomes | Emerging Cross-Sectional Technologies | 33 | Expired |
| US6544549B1 | Multilamellar coalescence vesicles (MLCV) containing biologically active compounds | Emerging Cross-Sectional Technologies | 24 | Expired |
| US5288499A | Sterodial liposomes | Emerging Cross-Sectional Technologies | 20 | Expired |
| US5231112A | Compositions containing tris salt of cholesterol hemisuccinate and antifungal | Emerging Cross-Sectional Technologies | 15 | Expired |
| US5897873A | Affinity associated vaccine | Emerging Cross-Sectional Technologies | 14 | Expired |
| US6312718A | Vaccine for B-cell malignancies | Human Necessities | 7 | Expired |
| US6207170A | Patient-specific white blood cell malignancy vaccine from membrane-proteoliposomes | Human Necessities | 2 | Expired |
| US11766473B2 | Therapeutic cancer vaccine containing tumor-associated neoantigens and immunostimulants in a deliver system | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.